Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 7/20 | 0.52 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 3/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12345854 | 1.00 | METAP1 (0.52) | METAP1METAP2SCN9AALOX12EPHX2 | |
| SCHEMBL2234699 | 1.00 | METAP1 (0.52) | METAP1METAP2SCN9AALOX12EPHX2 | |
| SCHEMBL2236914 | 0.87 | METAP1 (0.57) | METAP1METAP2SCN9AXIAP | |
| SCHEMBL12345846 | 0.87 | METAP1 (0.57) | METAP1METAP2SCN9AXIAP | |
| SCHEMBL2236923 | 0.87 | METAP1 (0.57) | METAP1METAP2SCN9AXIAP | |
| SCHEMBL2236932 | 0.87 | METAP1 (0.57) | METAP1METAP2SCN9AXIAP | |
| SCHEMBL14010764 | 0.80 | METAP1 (0.54) | METAP1METAP2SCN9AXIAP | |
| SCHEMBL14010761 | 0.80 | METAP1 (0.54) | METAP1METAP2SCN9AXIAP | |
| SCHEMBL4497937 | 0.80 | METAP1 (0.69) | METAP1METAP2EPHX2 | |
| SCHEMBL4497926 | 0.80 | METAP1 (0.69) | METAP1METAP2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994161-B2 | Derivatives of 2-alkoxy-3,4,5-trihydroxy-alkyl amides, preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | claimed |
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | claimed |
| US-7994161-B2 | Derivatives of 2-alkoxy-3,4,5-trihydroxy-alkyl amides, preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
| EP-2029555-A2 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | Sanofi-Aventis (FR) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007135295-A2 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135295-A2 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | CYP4B1, AADAC, ALKBH3 | METAP1 2962/4885METAP2 1628/4885SCN9A 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.